$114.08 Million in Sales Expected for Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) This Quarter

Equities analysts predict that Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) will post $114.08 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Biohaven Pharmaceutical’s earnings. The lowest sales estimate is $99.51 million and the highest is $124.35 million. Biohaven Pharmaceutical reported sales of $17.66 million during the same quarter last year, which indicates a positive year-over-year growth rate of 546%. The business is scheduled to issue its next earnings results on Monday, November 8th.

On average, analysts expect that Biohaven Pharmaceutical will report full year sales of $391.08 million for the current financial year, with estimates ranging from $357.34 million to $443.71 million. For the next fiscal year, analysts anticipate that the firm will report sales of $747.10 million, with estimates ranging from $664.56 million to $872.21 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Biohaven Pharmaceutical.

Biohaven Pharmaceutical (NYSE:BHVN) last announced its quarterly earnings data on Sunday, August 8th. The company reported ($3.23) EPS for the quarter, missing the consensus estimate of ($2.77) by ($0.46). The business had revenue of $92.93 million for the quarter, compared to analyst estimates of $85.85 million. During the same period last year, the firm posted ($2.55) EPS. The company’s revenue for the quarter was up 858.3% on a year-over-year basis.

BHVN has been the subject of several research reports. Morgan Stanley lifted their price objective on shares of Biohaven Pharmaceutical from $69.00 to $107.00 and gave the company an “equal weight” rating in a research note on Friday, July 16th. Mizuho lifted their target price on shares of Biohaven Pharmaceutical from $92.00 to $134.00 and gave the company a “buy” rating in a report on Monday, July 12th. UBS Group lowered shares of Biohaven Pharmaceutical from a “buy” rating to a “neutral” rating and lifted their target price for the company from $108.00 to $109.00 in a report on Tuesday, August 10th. Canaccord Genuity lifted their target price on shares of Biohaven Pharmaceutical from $101.00 to $150.00 and gave the company a “buy” rating in a report on Tuesday, August 3rd. Finally, HC Wainwright lifted their target price on shares of Biohaven Pharmaceutical from $111.00 to $135.00 and gave the company a “buy” rating in a report on Thursday, July 8th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $124.27.

A number of institutional investors have recently modified their holdings of BHVN. Harbor Investment Advisory LLC lifted its stake in Biohaven Pharmaceutical by 3,470.0% in the 2nd quarter. Harbor Investment Advisory LLC now owns 357 shares of the company’s stock valued at $35,000 after buying an additional 347 shares in the last quarter. Elkhorn Partners Limited Partnership purchased a new position in Biohaven Pharmaceutical in the 1st quarter valued at about $68,000. Lazard Asset Management LLC lifted its stake in Biohaven Pharmaceutical by 732.1% in the 2nd quarter. Lazard Asset Management LLC now owns 882 shares of the company’s stock valued at $85,000 after buying an additional 776 shares in the last quarter. E Fund Management Co. Ltd. purchased a new position in Biohaven Pharmaceutical in the 1st quarter valued at about $116,000. Finally, Harbour Investments Inc. purchased a new position in Biohaven Pharmaceutical in the 1st quarter valued at about $124,000. 92.14% of the stock is currently owned by hedge funds and other institutional investors.

NYSE BHVN traded up $0.63 on Friday, hitting $135.97. 6,704 shares of the company’s stock traded hands, compared to its average volume of 621,735. Biohaven Pharmaceutical has a 1-year low of $57.70 and a 1-year high of $139.50. The firm’s 50-day moving average price is $124.29 and its two-hundred day moving average price is $95.81. The firm has a market capitalization of $8.89 billion, a PE ratio of -9.44 and a beta of 1.03.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Co Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators.

Recommended Story: What is Cost of Goods Sold (COGS)?

Get a free copy of the Zacks research report on Biohaven Pharmaceutical (BHVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.